{"congress":"ASCO2026","meeting_name":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"total_abstracts":6656,"filtered":500,"offset":0,"limit":50,"has_more":true,"abstracts":[{"abstract_id":"2026-9871","abstract_number":"9871","doi":"10.1200/JCO.2026.44.17_suppl.9871","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-01","time_local":"13:00","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-556","authors":[{"name":"L. Paz-Ares","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"G. Curigliano","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"S. Tolaney","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"T. Mok","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"P. Schmid","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-556","nct_id":"NCT04698869","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":19.9,"unit":"months","hr":0.64,"hr_ci95":[0.54,0.74],"p":"0.002"},{"name":"PFS","value":8.3,"unit":"months","hr":0.68,"hr_ci95":[0.57,0.76],"p":"0.002"},{"name":"ORR","value":64.8,"unit":"percent"}],"summary":"Median OS 19.9 months. HR 0.64 (95% CI 0.54–0.74). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-01T13:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4001","abstract_number":"LBA4001","doi":"10.1200/JCO.2026.44.17_suppl.LBA4001","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"16:00","room":"S100A"},"title":"Long-term follow-up of Keytruda maintenance for NSCLC: KEYNOTE-890","authors":[{"name":"M. Krop","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"A. Spira","affiliation":"Mayo Clinic","is_presenter":false},{"name":"F. Andre","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-890","nct_id":"NCT09295643","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":27.2,"unit":"months","hr":0.79,"hr_ci95":[0.68,0.9],"p":"0.002"},{"name":"PFS","value":9.1,"unit":"months","hr":0.74,"hr_ci95":[0.64,0.91],"p":"0.002"},{"name":"ORR","value":63.5,"unit":"percent"}],"summary":"Median OS 27.2 months. HR 0.79 (95% CI 0.68–0.9). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9022","abstract_number":"9022","doi":"10.1200/JCO.2026.44.17_suppl.9022","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"18:30","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Keytruda in patients with NSCLC","authors":[{"name":"E. Winer","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"M. Reck","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"G. Curigliano","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-471","nct_id":"NCT20575480","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":22,"unit":"months","hr":0.76,"hr_ci95":[0.65,0.87],"p":"<0.001"},{"name":"PFS","value":11,"unit":"months","hr":0.79,"hr_ci95":[0.62,0.9],"p":"<0.001"},{"name":"ORR","value":49.3,"unit":"percent"}],"summary":"Median OS 22 months. HR 0.76 (95% CI 0.65–0.87). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-02T18:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10063","abstract_number":"10063","doi":"10.1200/JCO.2026.44.17_suppl.10063","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Poster Session","title":"Poster Session: Melanoma","date":"2026-06-02","time_local":"14:00","room":"S406"},"title":"Quality of life outcomes with Keytruda in patients with metastatic melanoma","authors":[{"name":"S. Tolaney","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"C. Robert","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"C. Saura","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"R. Herbst","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"M. Krop","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-471","nct_id":"NCT87748367","phase":"II"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":48.5,"unit":"months","hr":0.83,"hr_ci95":[0.75,0.91],"p":"0.002"},{"name":"PFS","value":14.3,"unit":"months","hr":0.88,"hr_ci95":[0.78,0.93],"p":"0.002"},{"name":"ORR","value":56.4,"unit":"percent"}],"summary":"Median OS 48.5 months. HR 0.83 (95% CI 0.75–0.91). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T14:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6184","abstract_number":"6184","doi":"10.1200/JCO.2026.44.17_suppl.6184","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-02","time_local":"21:30","room":"E450"},"title":"Real-world effectiveness of Keytruda vs standard of care in RCC","authors":[{"name":"L. Paz-Ares","affiliation":"University of Chicago","is_presenter":true},{"name":"S. Tolaney","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-70","nct_id":"NCT94215795","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":52.8,"unit":"months","hr":0.86,"hr_ci95":[0.73,0.99],"p":"0.002"},{"name":"PFS","value":18.9,"unit":"months","hr":0.83,"hr_ci95":[0.7,0.98],"p":"0.002"},{"name":"ORR","value":57.3,"unit":"percent"}],"summary":"Median OS 52.8 months. HR 0.86 (95% CI 0.73–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4005","abstract_number":"LBA4005","doi":"10.1200/JCO.2026.44.17_suppl.LBA4005","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"16:45","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-399","authors":[{"name":"M.C. Garassino","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"C. Robert","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-399","nct_id":"NCT80376196","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":40.4,"unit":"months","hr":0.71,"hr_ci95":[0.62,0.8],"p":"0.08"},{"name":"PFS","value":13.6,"unit":"months","hr":0.74,"hr_ci95":[0.62,0.77],"p":"0.08"},{"name":"ORR","value":53.2,"unit":"percent"}],"summary":"Median OS 40.4 months. HR 0.71 (95% CI 0.62–0.8). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T16:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9004","abstract_number":"9004","doi":"10.1200/JCO.2026.44.17_suppl.9004","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-05","time_local":"14:15","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-135","authors":[{"name":"H. Borghaei","affiliation":"University of Chicago","is_presenter":true},{"name":"A. Spira","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-135","nct_id":"NCT97266990","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":15.2,"unit":"months","hr":0.71,"hr_ci95":[0.58,0.84],"p":"0.014"},{"name":"PFS","value":4.5,"unit":"months","hr":0.76,"hr_ci95":[0.6,0.84],"p":"0.014"},{"name":"ORR","value":56.4,"unit":"percent"}],"summary":"Median OS 15.2 months. HR 0.71 (95% CI 0.58–0.84). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-05T14:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9482","abstract_number":"9482","doi":"10.1200/JCO.2026.44.17_suppl.9482","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Education Session","title":"Education Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"19:00","room":"E450"},"title":"Long-term follow-up of Keytruda maintenance for NSCLC: KEYNOTE-876","authors":[{"name":"H. Borghaei","affiliation":"University of Chicago","is_presenter":true},{"name":"S. Peters","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"M. Krop","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"C. Robert","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-876","nct_id":"NCT84618685","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":29.7,"unit":"months","hr":0.8,"hr_ci95":[0.7,0.9],"p":"0.014"},{"name":"PFS","value":11.5,"unit":"months","hr":0.75,"hr_ci95":[0.67,0.89],"p":"0.014"},{"name":"ORR","value":61.1,"unit":"percent"}],"summary":"Median OS 29.7 months. HR 0.8 (95% CI 0.7–0.9). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T19:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10382","abstract_number":"10382","doi":"10.1200/JCO.2026.44.17_suppl.10382","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Melanoma","date":"2026-06-03","time_local":"20:30","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-352","authors":[{"name":"N. Rizvi","affiliation":"MD Anderson Cancer Center","is_presenter":true},{"name":"J. Brahmer","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"M. Reck","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"H. Borghaei","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-352","nct_id":"NCT42681886","phase":"III"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":45,"unit":"months","hr":0.61,"hr_ci95":[0.5,0.72],"p":"0.08"},{"name":"PFS","value":13.5,"unit":"months","hr":0.66,"hr_ci95":[0.51,0.71],"p":"0.08"},{"name":"ORR","value":51.8,"unit":"percent"}],"summary":"Median OS 45 months. HR 0.61 (95% CI 0.5–0.72). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9350","abstract_number":"9350","doi":"10.1200/JCO.2026.44.17_suppl.9350","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-01","time_local":"13:30","room":"Hall B1"},"title":"Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-731 study)","authors":[{"name":"S. Peters","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"T. Mok","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"J. Cortes","affiliation":"Mayo Clinic","is_presenter":false},{"name":"S. Modi","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-731","nct_id":"NCT17606604","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":24.8,"unit":"months","hr":0.7,"hr_ci95":[0.58,0.82],"p":"0.014"},{"name":"PFS","value":8.1,"unit":"months","hr":0.72,"hr_ci95":[0.61,0.8],"p":"0.014"},{"name":"ORR","value":58.4,"unit":"percent"}],"summary":"Median OS 24.8 months. HR 0.7 (95% CI 0.58–0.82). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-01T13:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9509","abstract_number":"9509","doi":"10.1200/JCO.2026.44.17_suppl.9509","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-04","time_local":"16:45","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Keytruda vs standard of care in SCLC","authors":[{"name":"S. Peters","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"R. Herbst","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"E. Winer","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-477","nct_id":"NCT20866161","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":14,"unit":"months","hr":0.8,"hr_ci95":[0.67,0.93],"p":"0.014"},{"name":"PFS","value":5.2,"unit":"months","hr":0.79,"hr_ci95":[0.68,0.9],"p":"0.014"},{"name":"ORR","value":60.7,"unit":"percent"}],"summary":"Median OS 14 months. HR 0.8 (95% CI 0.67–0.93). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T16:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9748","abstract_number":"9748","doi":"10.1200/JCO.2026.44.17_suppl.9748","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Poster Session","title":"Poster Session: Melanoma","date":"2026-06-04","time_local":"14:15","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma","authors":[{"name":"S. Tolaney","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"H. Borghaei","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-364","nct_id":"NCT18335148","phase":"III"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":52,"unit":"months","hr":0.84,"hr_ci95":[0.7,0.98],"p":"<0.001"},{"name":"PFS","value":13.9,"unit":"months","hr":0.8,"hr_ci95":[0.67,0.99],"p":"<0.001"},{"name":"ORR","value":48.5,"unit":"percent"}],"summary":"Median OS 52 months. HR 0.84 (95% CI 0.7–0.98). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T14:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10255","abstract_number":"10255","doi":"10.1200/JCO.2026.44.17_suppl.10255","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Melanoma","date":"2026-06-04","time_local":"21:30","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-748","authors":[{"name":"S. Modi","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"S. Tolaney","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"M.C. Garassino","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-748","nct_id":"NCT18298255","phase":"II"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":61.3,"unit":"months","hr":0.86,"hr_ci95":[0.74,0.98],"p":"<0.001"},{"name":"PFS","value":13.1,"unit":"months","hr":0.85,"hr_ci95":[0.78,0.97],"p":"<0.001"},{"name":"ORR","value":52.7,"unit":"percent"}],"summary":"Median OS 61.3 months. HR 0.86 (95% CI 0.74–0.98). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1347","abstract_number":"1347","doi":"10.1200/JCO.2026.44.17_suppl.1347","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"21:30","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-954","authors":[{"name":"N. Rizvi","affiliation":"Mayo Clinic","is_presenter":true},{"name":"S. Peters","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-954","nct_id":"NCT49932333","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":19,"unit":"months","hr":0.67,"hr_ci95":[0.53,0.81],"p":"<0.001"},{"name":"PFS","value":10.4,"unit":"months","hr":0.65,"hr_ci95":[0.55,0.77],"p":"<0.001"},{"name":"ORR","value":45.9,"unit":"percent"}],"summary":"Median OS 19 months. HR 0.67 (95% CI 0.53–0.81). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1333","abstract_number":"1333","doi":"10.1200/JCO.2026.44.17_suppl.1333","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"19:30","room":"S100A"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-507","authors":[{"name":"J. Brahmer","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"T. Mok","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-507","nct_id":"NCT60525440","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":25.8,"unit":"months","hr":0.55,"hr_ci95":[0.46,0.64],"p":"0.08"},{"name":"PFS","value":9.8,"unit":"months","hr":0.58,"hr_ci95":[0.44,0.68],"p":"0.08"},{"name":"ORR","value":54.4,"unit":"percent"}],"summary":"Median OS 25.8 months. HR 0.55 (95% CI 0.46–0.64). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T19:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9155","abstract_number":"9155","doi":"10.1200/JCO.2026.44.17_suppl.9155","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-03","time_local":"16:00","room":"S406"},"title":"Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-518 study)","authors":[{"name":"S. Tolaney","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"T. Mok","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"G. Curigliano","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-518","nct_id":"NCT22923964","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":26.9,"unit":"months","hr":0.55,"hr_ci95":[0.43,0.67],"p":"0.08"},{"name":"PFS","value":8.7,"unit":"months","hr":0.59,"hr_ci95":[0.4,0.67],"p":"0.08"},{"name":"ORR","value":44.2,"unit":"percent"}],"summary":"Median OS 26.9 months. HR 0.55 (95% CI 0.43–0.67). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9243","abstract_number":"9243","doi":"10.1200/JCO.2026.44.17_suppl.9243","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Small Cell","date":"2026-06-01","time_local":"13:00","room":"Arie Crown Theater"},"title":"Quality of life outcomes with Keytruda in patients with SCLC","authors":[{"name":"S. Tolaney","affiliation":"Karolinska Institute","is_presenter":true},{"name":"C. Robert","affiliation":"Mayo Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-315","nct_id":"NCT02307004","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":11.6,"unit":"months","hr":0.69,"hr_ci95":[0.61,0.77],"p":"0.014"},{"name":"PFS","value":6.9,"unit":"months","hr":0.69,"hr_ci95":[0.61,0.78],"p":"0.014"},{"name":"ORR","value":68.3,"unit":"percent"}],"summary":"Median OS 11.6 months. HR 0.69 (95% CI 0.61–0.77). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-01T13:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1755","abstract_number":"1755","doi":"10.1200/JCO.2026.44.17_suppl.1755","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"19:15","room":"S406"},"title":"KEYNOTE-624: Keytruda (pembrolizumab) 1L in TNBC","authors":[{"name":"M.C. Garassino","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"S. Modi","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"S. Antonia","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-624","nct_id":"NCT81829174","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":22.3,"unit":"months","hr":0.88,"hr_ci95":[0.76,0.99],"p":"0.08"},{"name":"PFS","value":10.9,"unit":"months","hr":0.83,"hr_ci95":[0.74,0.99],"p":"0.08"},{"name":"ORR","value":48.6,"unit":"percent"}],"summary":"Median OS 22.3 months. HR 0.88 (95% CI 0.76–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T19:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9455","abstract_number":"9455","doi":"10.1200/JCO.2026.44.17_suppl.9455","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"13:00","room":"S406"},"title":"Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-647 study)","authors":[{"name":"E. Winer","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"H. Borghaei","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"M. Krop","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"G. Curigliano","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-647","nct_id":"NCT33039765","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":27.1,"unit":"months","hr":0.86,"hr_ci95":[0.77,0.95],"p":"0.002"},{"name":"PFS","value":10.5,"unit":"months","hr":0.9,"hr_ci95":[0.81,0.92],"p":"0.002"},{"name":"ORR","value":59.5,"unit":"percent"}],"summary":"Median OS 27.1 months. HR 0.86 (95% CI 0.77–0.95). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T13:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6963","abstract_number":"6963","doi":"10.1200/JCO.2026.44.17_suppl.6963","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-02","time_local":"21:00","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-409","authors":[{"name":"H. Borghaei","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"S. Peters","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"E. Winer","affiliation":"University of Chicago","is_presenter":false},{"name":"R. Herbst","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-409","nct_id":"NCT37979647","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":36.4,"unit":"months","hr":0.76,"hr_ci95":[0.63,0.89],"p":"0.03"},{"name":"PFS","value":14.8,"unit":"months","hr":0.79,"hr_ci95":[0.63,0.86],"p":"0.03"},{"name":"ORR","value":67.6,"unit":"percent"}],"summary":"Median OS 36.4 months. HR 0.76 (95% CI 0.63–0.89). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9928","abstract_number":"9928","doi":"10.1200/JCO.2026.44.17_suppl.9928","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Small Cell","date":"2026-06-05","time_local":"21:45","room":"S100A"},"title":"Long-term follow-up of Keytruda 3L+ for SCLC: KEYNOTE-244","authors":[{"name":"J. Cortes","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"A. Spira","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"M. Reck","affiliation":"University of Chicago","is_presenter":false},{"name":"F. Andre","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"S. Peters","affiliation":"Mayo Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-244","nct_id":"NCT57798798","phase":"II"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":12.5,"unit":"months","hr":0.68,"hr_ci95":[0.58,0.78],"p":"0.08"},{"name":"PFS","value":5.9,"unit":"months","hr":0.64,"hr_ci95":[0.58,0.78],"p":"0.08"},{"name":"ORR","value":73.5,"unit":"percent"}],"summary":"Median OS 12.5 months. HR 0.68 (95% CI 0.58–0.78). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T21:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1934","abstract_number":"1934","doi":"10.1200/JCO.2026.44.17_suppl.1934","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"20:15","room":"Arie Crown Theater"},"title":"Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-620 study)","authors":[{"name":"G. Curigliano","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-620","nct_id":"NCT67938365","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":23,"unit":"months","hr":0.83,"hr_ci95":[0.71,0.95],"p":"0.014"},{"name":"PFS","value":9.1,"unit":"months","hr":0.79,"hr_ci95":[0.74,0.93],"p":"0.014"},{"name":"ORR","value":38.2,"unit":"percent"}],"summary":"Median OS 23 months. HR 0.83 (95% CI 0.71–0.95). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T20:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9071","abstract_number":"9071","doi":"10.1200/JCO.2026.44.17_suppl.9071","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-05","time_local":"16:00","room":"Arie Crown Theater"},"title":"Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-900 study)","authors":[{"name":"H. Rugo","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"P. Schmid","affiliation":"Mayo Clinic","is_presenter":false},{"name":"J. Brahmer","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-900","nct_id":"NCT27121213","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":28.5,"unit":"months","hr":0.68,"hr_ci95":[0.57,0.79],"p":"0.002"},{"name":"PFS","value":9,"unit":"months","hr":0.69,"hr_ci95":[0.54,0.76],"p":"0.002"},{"name":"ORR","value":46,"unit":"percent"}],"summary":"Median OS 28.5 months. HR 0.68 (95% CI 0.57–0.79). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9758","abstract_number":"9758","doi":"10.1200/JCO.2026.44.17_suppl.9758","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-04","time_local":"16:45","room":"Hall B1"},"title":"Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-743 study)","authors":[{"name":"M.C. Garassino","affiliation":"Stanford Cancer Institute","is_presenter":true},{"name":"P. Schmid","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"M. Krop","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"H. Rugo","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-743","nct_id":"NCT49235427","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":10.7,"unit":"months","hr":0.84,"hr_ci95":[0.74,0.94],"p":"0.08"},{"name":"PFS","value":6.8,"unit":"months","hr":0.79,"hr_ci95":[0.76,0.9],"p":"0.08"},{"name":"ORR","value":63.5,"unit":"percent"}],"summary":"Median OS 10.7 months. HR 0.84 (95% CI 0.74–0.94). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T16:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6353","abstract_number":"6353","doi":"10.1200/JCO.2026.44.17_suppl.6353","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"13:15","room":"Arie Crown Theater"},"title":"Long-term follow-up of Keytruda 2L for RCC: KEYNOTE-473","authors":[{"name":"C. Robert","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"S. Tolaney","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"T. Mok","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"P. Schmid","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-473","nct_id":"NCT97070182","phase":"II"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":50,"unit":"months","hr":0.76,"hr_ci95":[0.64,0.88],"p":"0.08"},{"name":"PFS","value":22.1,"unit":"months","hr":0.75,"hr_ci95":[0.62,0.86],"p":"0.08"},{"name":"ORR","value":58.2,"unit":"percent"}],"summary":"Median OS 50 months. HR 0.76 (95% CI 0.64–0.88). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T13:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9219","abstract_number":"9219","doi":"10.1200/JCO.2026.44.17_suppl.9219","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-01","time_local":"14:30","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-835","authors":[{"name":"L. Paz-Ares","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"G. Curigliano","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"F. Andre","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"M.C. Garassino","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"T. Mok","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-835","nct_id":"NCT27962379","phase":"II"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":10.2,"unit":"months","hr":0.86,"hr_ci95":[0.74,0.98],"p":"0.03"},{"name":"PFS","value":5.3,"unit":"months","hr":0.86,"hr_ci95":[0.71,0.96],"p":"0.03"},{"name":"ORR","value":65.6,"unit":"percent"}],"summary":"Median OS 10.2 months. HR 0.86 (95% CI 0.74–0.98). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-01T14:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9846","abstract_number":"9846","doi":"10.1200/JCO.2026.44.17_suppl.9846","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"16:15","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-574","authors":[{"name":"H. Rugo","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"A. Spira","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"S. Peters","affiliation":"National Cancer Center Japan","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-574","nct_id":"NCT60327376","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":24.4,"unit":"months","hr":0.58,"hr_ci95":[0.44,0.72],"p":"0.08"},{"name":"PFS","value":8.1,"unit":"months","hr":0.57,"hr_ci95":[0.46,0.72],"p":"0.08"},{"name":"ORR","value":59.9,"unit":"percent"}],"summary":"Median OS 24.4 months. HR 0.58 (95% CI 0.44–0.72). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T16:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6514","abstract_number":"6514","doi":"10.1200/JCO.2026.44.17_suppl.6514","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-04","time_local":"21:15","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-46","authors":[{"name":"J. Cortes","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-46","nct_id":"NCT91383730","phase":"II"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":48.4,"unit":"months","hr":0.61,"hr_ci95":[0.52,0.7],"p":"<0.001"},{"name":"PFS","value":15.3,"unit":"months","hr":0.62,"hr_ci95":[0.52,0.69],"p":"<0.001"},{"name":"ORR","value":54.2,"unit":"percent"}],"summary":"Median OS 48.4 months. HR 0.61 (95% CI 0.52–0.7). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T21:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9621","abstract_number":"9621","doi":"10.1200/JCO.2026.44.17_suppl.9621","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Education Session","title":"Education Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-05","time_local":"14:45","room":"S406"},"title":"Real-world effectiveness of Keytruda vs standard of care in NSCLC","authors":[{"name":"C. Robert","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"F. Andre","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"E. Winer","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"A. Spira","affiliation":"National Cancer Center Japan","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-952","nct_id":"NCT27846448","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":29.4,"unit":"months","hr":0.9,"hr_ci95":[0.76,0.99],"p":"0.002"},{"name":"PFS","value":10.9,"unit":"months","hr":0.89,"hr_ci95":[0.77,0.99],"p":"0.002"},{"name":"ORR","value":44.1,"unit":"percent"}],"summary":"Median OS 29.4 months. HR 0.9 (95% CI 0.76–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T14:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9402","abstract_number":"9402","doi":"10.1200/JCO.2026.44.17_suppl.9402","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-01","time_local":"13:45","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-642","authors":[{"name":"S. Modi","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"P. Schmid","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"H. Rugo","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-642","nct_id":"NCT30148315","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":18.9,"unit":"months","hr":0.91,"hr_ci95":[0.78,0.99],"p":"0.002"},{"name":"PFS","value":10.9,"unit":"months","hr":0.89,"hr_ci95":[0.77,0.99],"p":"0.002"},{"name":"ORR","value":59.3,"unit":"percent"}],"summary":"Median OS 18.9 months. HR 0.91 (95% CI 0.78–0.99). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-01T13:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1935","abstract_number":"1935","doi":"10.1200/JCO.2026.44.17_suppl.1935","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"21:30","room":"E450"},"title":"Quality of life outcomes with Keytruda in patients with TNBC","authors":[{"name":"C. Robert","affiliation":"Karolinska Institute","is_presenter":true},{"name":"J. Cortes","affiliation":"Mayo Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-295","nct_id":"NCT89845260","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":24.8,"unit":"months","hr":0.68,"hr_ci95":[0.57,0.79],"p":"0.03"},{"name":"PFS","value":9,"unit":"months","hr":0.72,"hr_ci95":[0.54,0.81],"p":"0.03"},{"name":"ORR","value":53.4,"unit":"percent"}],"summary":"Median OS 24.8 months. HR 0.68 (95% CI 0.57–0.79). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9379","abstract_number":"9379","doi":"10.1200/JCO.2026.44.17_suppl.9379","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-01","time_local":"21:30","room":"E450"},"title":"Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-744","authors":[{"name":"J. Brahmer","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"G. Curigliano","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"C. Saura","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-744","nct_id":"NCT18464476","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":12.3,"unit":"months","hr":0.61,"hr_ci95":[0.5,0.72],"p":"0.03"},{"name":"PFS","value":4.5,"unit":"months","hr":0.56,"hr_ci95":[0.48,0.7],"p":"0.03"},{"name":"ORR","value":57.6,"unit":"percent"}],"summary":"Median OS 12.3 months. HR 0.61 (95% CI 0.5–0.72). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-01T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-TPS8032","abstract_number":"TPS8032","doi":"10.1200/JCO.2026.44.17_suppl.TPS8032","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"21:00","room":"Hall B1"},"title":"KEYNOTE-444: Keytruda (pembrolizumab) 1L in RCC","authors":[{"name":"C. Saura","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"S. Peters","affiliation":"Mayo Clinic","is_presenter":false},{"name":"E. Winer","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-444","nct_id":"NCT26850171","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":49.7,"unit":"months","hr":0.56,"hr_ci95":[0.44,0.68],"p":"0.03"},{"name":"PFS","value":14.8,"unit":"months","hr":0.55,"hr_ci95":[0.46,0.65],"p":"0.03"},{"name":"ORR","value":52.6,"unit":"percent"}],"summary":"Median OS 49.7 months. HR 0.56 (95% CI 0.44–0.68). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1621","abstract_number":"1621","doi":"10.1200/JCO.2026.44.17_suppl.1621","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"18:30","room":"Arie Crown Theater"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-583","authors":[{"name":"S. Antonia","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"M.C. Garassino","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-583","nct_id":"NCT77557714","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":19.6,"unit":"months","hr":0.74,"hr_ci95":[0.62,0.86],"p":"<0.001"},{"name":"PFS","value":8.1,"unit":"months","hr":0.75,"hr_ci95":[0.61,0.84],"p":"<0.001"},{"name":"ORR","value":38.3,"unit":"percent"}],"summary":"Median OS 19.6 months. HR 0.74 (95% CI 0.62–0.86). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T18:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4034","abstract_number":"LBA4034","doi":"10.1200/JCO.2026.44.17_suppl.LBA4034","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"13:30","room":"S406"},"title":"Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-682 study)","authors":[{"name":"S. Peters","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"M. Reck","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"N. Rizvi","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-682","nct_id":"NCT30405663","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":24.3,"unit":"months","hr":0.69,"hr_ci95":[0.55,0.83],"p":"0.08"},{"name":"PFS","value":10.2,"unit":"months","hr":0.74,"hr_ci95":[0.52,0.82],"p":"0.08"},{"name":"ORR","value":35.3,"unit":"percent"}],"summary":"Median OS 24.3 months. HR 0.69 (95% CI 0.55–0.83). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T13:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9064","abstract_number":"9064","doi":"10.1200/JCO.2026.44.17_suppl.9064","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"21:00","room":"Arie Crown Theater"},"title":"KEYNOTE-677: Keytruda (pembrolizumab) 1L in NSCLC","authors":[{"name":"E. Winer","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"P. Schmid","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"A. Spira","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-677","nct_id":"NCT88908804","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":27.4,"unit":"months","hr":0.57,"hr_ci95":[0.45,0.69],"p":"0.014"},{"name":"PFS","value":11.1,"unit":"months","hr":0.53,"hr_ci95":[0.44,0.66],"p":"0.014"},{"name":"ORR","value":45.9,"unit":"percent"}],"summary":"Median OS 27.4 months. HR 0.57 (95% CI 0.45–0.69). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9945","abstract_number":"9945","doi":"10.1200/JCO.2026.44.17_suppl.9945","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-03","time_local":"15:00","room":"E450"},"title":"Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-261","authors":[{"name":"J. Brahmer","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"E. Winer","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"M. Krop","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-261","nct_id":"NCT86130810","phase":"II"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":15.5,"unit":"months","hr":0.89,"hr_ci95":[0.77,0.99],"p":"0.08"},{"name":"PFS","value":6.6,"unit":"months","hr":0.84,"hr_ci95":[0.76,0.96],"p":"0.08"},{"name":"ORR","value":74.1,"unit":"percent"}],"summary":"Median OS 15.5 months. HR 0.89 (95% CI 0.77–0.99). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T15:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10108","abstract_number":"10108","doi":"10.1200/JCO.2026.44.17_suppl.10108","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Poster Session","title":"Poster Session: Melanoma","date":"2026-06-02","time_local":"16:00","room":"Arie Crown Theater"},"title":"KEYNOTE-495: Keytruda (pembrolizumab) maintenance in metastatic melanoma","authors":[{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"S. Tolaney","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-495","nct_id":"NCT75646432","phase":"II"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":68.3,"unit":"months","hr":0.69,"hr_ci95":[0.6,0.78],"p":"0.03"},{"name":"PFS","value":11.6,"unit":"months","hr":0.73,"hr_ci95":[0.57,0.75],"p":"0.03"},{"name":"ORR","value":61.3,"unit":"percent"}],"summary":"Median OS 68.3 months. HR 0.69 (95% CI 0.6–0.78). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10036","abstract_number":"10036","doi":"10.1200/JCO.2026.44.17_suppl.10036","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Poster Session","title":"Poster Session: Melanoma","date":"2026-06-03","time_local":"13:30","room":"S406"},"title":"Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-94","authors":[{"name":"L. Paz-Ares","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"C. Saura","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"R. Herbst","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"S. Tolaney","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-94","nct_id":"NCT14858043","phase":"III"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":66.3,"unit":"months","hr":0.56,"hr_ci95":[0.47,0.65],"p":"0.002"},{"name":"PFS","value":11.3,"unit":"months","hr":0.55,"hr_ci95":[0.5,0.67],"p":"0.002"},{"name":"ORR","value":54.4,"unit":"percent"}],"summary":"Median OS 66.3 months. HR 0.56 (95% CI 0.47–0.65). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T13:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1893","abstract_number":"1893","doi":"10.1200/JCO.2026.44.17_suppl.1893","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"19:15","room":"S406"},"title":"KEYNOTE-322: Keytruda (pembrolizumab) neoadjuvant in TNBC","authors":[{"name":"P. Schmid","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-322","nct_id":"NCT84745331","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":18.4,"unit":"months","hr":0.67,"hr_ci95":[0.57,0.77],"p":"0.03"},{"name":"PFS","value":8.9,"unit":"months","hr":0.67,"hr_ci95":[0.56,0.76],"p":"0.03"},{"name":"ORR","value":51.3,"unit":"percent"}],"summary":"Median OS 18.4 months. HR 0.67 (95% CI 0.57–0.77). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T19:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-TPS8040","abstract_number":"TPS8040","doi":"10.1200/JCO.2026.44.17_suppl.TPS8040","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"18:00","room":"S100A"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-577","authors":[{"name":"N. Rizvi","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"P. Schmid","affiliation":"Mayo Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-577","nct_id":"NCT54162765","phase":"II"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":25.5,"unit":"months","hr":0.63,"hr_ci95":[0.54,0.72],"p":"0.03"},{"name":"PFS","value":9.2,"unit":"months","hr":0.66,"hr_ci95":[0.54,0.69],"p":"0.03"},{"name":"ORR","value":42.4,"unit":"percent"}],"summary":"Median OS 25.5 months. HR 0.63 (95% CI 0.54–0.72). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T18:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4041","abstract_number":"LBA4041","doi":"10.1200/JCO.2026.44.17_suppl.LBA4041","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"18:30","room":"Hall B1"},"title":"KEYNOTE-629: Keytruda (pembrolizumab) 2L in TNBC","authors":[{"name":"M. Reck","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"J. Cortes","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-629","nct_id":"NCT73637147","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":23.1,"unit":"months","hr":0.66,"hr_ci95":[0.52,0.8],"p":"0.014"},{"name":"PFS","value":7.3,"unit":"months","hr":0.63,"hr_ci95":[0.54,0.76],"p":"0.014"},{"name":"ORR","value":50.7,"unit":"percent"}],"summary":"Median OS 23.1 months. HR 0.66 (95% CI 0.52–0.8). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T18:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1913","abstract_number":"1913","doi":"10.1200/JCO.2026.44.17_suppl.1913","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"13:00","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-266","authors":[{"name":"J. Brahmer","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"C. Saura","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"S. Peters","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-266","nct_id":"NCT44546153","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":19.9,"unit":"months","hr":0.89,"hr_ci95":[0.8,0.98],"p":"0.03"},{"name":"PFS","value":9.7,"unit":"months","hr":0.88,"hr_ci95":[0.78,0.99],"p":"0.03"},{"name":"ORR","value":47.6,"unit":"percent"}],"summary":"Median OS 19.9 months. HR 0.89 (95% CI 0.8–0.98). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T13:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-10273","abstract_number":"10273","doi":"10.1200/JCO.2026.44.17_suppl.10273","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Melanoma","session":{"type":"Poster Session","title":"Poster Session: Melanoma","date":"2026-06-04","time_local":"13:15","room":"Arie Crown Theater"},"title":"Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-705 study)","authors":[{"name":"S. Modi","affiliation":"University of Chicago","is_presenter":true},{"name":"C. Saura","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"R. Herbst","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"S. Tolaney","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"H. Rugo","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-705","nct_id":"NCT04539897","phase":"II"},"indication":"metastatic melanoma","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":71.8,"unit":"months","hr":0.66,"hr_ci95":[0.57,0.75],"p":"0.002"},{"name":"PFS","value":12.4,"unit":"months","hr":0.65,"hr_ci95":[0.54,0.72],"p":"0.002"},{"name":"ORR","value":46.9,"unit":"percent"}],"summary":"Median OS 71.8 months. HR 0.66 (95% CI 0.57–0.75). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T13:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6036","abstract_number":"6036","doi":"10.1200/JCO.2026.44.17_suppl.6036","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-02","time_local":"21:30","room":"Arie Crown Theater"},"title":"Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-408 study)","authors":[{"name":"P. Schmid","affiliation":"Mayo Clinic","is_presenter":true},{"name":"S. Modi","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"R. Herbst","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-408","nct_id":"NCT72984226","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":47.6,"unit":"months","hr":0.9,"hr_ci95":[0.81,0.99],"p":"0.002"},{"name":"PFS","value":15.1,"unit":"months","hr":0.85,"hr_ci95":[0.81,0.99],"p":"0.002"},{"name":"ORR","value":52.6,"unit":"percent"}],"summary":"Median OS 47.6 months. HR 0.9 (95% CI 0.81–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T21:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6204","abstract_number":"6204","doi":"10.1200/JCO.2026.44.17_suppl.6204","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"18:45","room":"E450"},"title":"KEYNOTE-704: Keytruda (pembrolizumab) 2L in RCC","authors":[{"name":"M. Reck","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"H. Borghaei","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"E. Winer","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"S. Modi","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-704","nct_id":"NCT91344914","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":50.4,"unit":"months","hr":0.84,"hr_ci95":[0.72,0.96],"p":"0.002"},{"name":"PFS","value":22.4,"unit":"months","hr":0.83,"hr_ci95":[0.68,0.94],"p":"0.002"},{"name":"ORR","value":68,"unit":"percent"}],"summary":"Median OS 50.4 months. HR 0.84 (95% CI 0.72–0.96). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T18:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9148","abstract_number":"9148","doi":"10.1200/JCO.2026.44.17_suppl.9148","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"21:45","room":"Hall B1"},"title":"Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-602 study)","authors":[{"name":"T. Mok","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"R. Herbst","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"J. Brahmer","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"P. Schmid","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-602","nct_id":"NCT57279572","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":24.6,"unit":"months","hr":0.79,"hr_ci95":[0.66,0.92],"p":"0.08"},{"name":"PFS","value":11.4,"unit":"months","hr":0.82,"hr_ci95":[0.69,0.91],"p":"0.08"},{"name":"ORR","value":47.9,"unit":"percent"}],"summary":"Median OS 24.6 months. HR 0.79 (95% CI 0.66–0.92). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-02T21:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9440","abstract_number":"9440","doi":"10.1200/JCO.2026.44.17_suppl.9440","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Small Cell","date":"2026-06-05","time_local":"16:15","room":"Arie Crown Theater"},"title":"Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-702","authors":[{"name":"C. Robert","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"T. Mok","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"M. Krop","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"J. Brahmer","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"P. Schmid","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-702","nct_id":"NCT71761965","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":13.8,"unit":"months","hr":0.64,"hr_ci95":[0.52,0.76],"p":"0.002"},{"name":"PFS","value":4.6,"unit":"months","hr":0.69,"hr_ci95":[0.52,0.75],"p":"0.002"},{"name":"ORR","value":67.3,"unit":"percent"}],"summary":"Median OS 13.8 months. HR 0.64 (95% CI 0.52–0.76). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T16:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1840","abstract_number":"1840","doi":"10.1200/JCO.2026.44.17_suppl.1840","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"16:15","room":"Hall B1"},"title":"KEYNOTE-999: Keytruda (pembrolizumab) 2L in TNBC","authors":[{"name":"C. Saura","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":true},{"name":"S. Peters","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-999","nct_id":"NCT95882996","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":23.7,"unit":"months","hr":0.57,"hr_ci95":[0.47,0.67],"p":"<0.001"},{"name":"PFS","value":7.1,"unit":"months","hr":0.57,"hr_ci95":[0.45,0.69],"p":"<0.001"},{"name":"ORR","value":36.4,"unit":"percent"}],"summary":"Median OS 23.7 months. HR 0.57 (95% CI 0.47–0.67). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T16:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1575","abstract_number":"1575","doi":"10.1200/JCO.2026.44.17_suppl.1575","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"19:45","room":"Arie Crown Theater"},"title":"Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-720","authors":[{"name":"E. Winer","affiliation":"Karolinska Institute","is_presenter":true},{"name":"T. Mok","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"A. Spira","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"R. Herbst","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-720","nct_id":"NCT02724906","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":18.5,"unit":"months","hr":0.61,"hr_ci95":[0.5,0.72],"p":"<0.001"},{"name":"PFS","value":7,"unit":"months","hr":0.58,"hr_ci95":[0.53,0.74],"p":"<0.001"},{"name":"ORR","value":39.7,"unit":"percent"}],"summary":"Median OS 18.5 months. HR 0.61 (95% CI 0.5–0.72). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T19:45:00-05:00","status":"embargoed"}}]}